Genetic products which are differentially expressed in tumours and use thereof

Details for Australian Patent Application No. 2004272270 (hide)

Owner Ganymed Pharmaceuticals AG

Inventors Koslowski, Michael; Tureci, Ozlem; Sahin, Ugur

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2004272270

PCT Pub. Number WO2005/026205

Priority 103 41 812.1 10.09.03 DE

Filing date 10 September 2004

Wipo publication date 24 March 2005

Acceptance publication date 21 July 2011

International Classifications

C07K 14/47 (2006.01) Peptides having more than 20 amino acids

C07K 16/30 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

Event Publications

30 March 2006 PCT application entered the National Phase

  PCT publication WO2005/026205 Priority application(s): WO2005/026205

21 July 2011 Application Accepted

  Published as AU-B-2004272270

17 November 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004272272-Base-substituted benzylamine analogs for use as coagulation factor Xa inhibitors, the production and use thereof

2004272265-Method for the extraction of corkcontaining material